Related Experiment Videos
[Antiplatelet therapy in 2005]
1Service de Pathologie Vasculaire, Hôpital Erasme, Bruxelles.
Revue Medicale De Bruxelles
|February 4, 2005
Summary
Atherothrombosis, a cause of ischemic events, can be managed with antiplatelet agents like aspirin. New data guides optimal use of aspirin, clopidogrel, dipyridamole, and glycoprotein IIb/IIIa antagonists for preventing vascular events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Atherothrombosis is a significant cause of ischemic events in cerebral, coronary, and peripheral arteries.
- Antiplatelet agents are crucial for secondary prevention in patients with established vascular disease or risk factors.
Purpose:
- To review current data on antiplatelet agents, including aspirin, clopidogrel, dipyridamole, and glycoprotein IIb/IIIa antagonists.
- To provide practical therapeutic recommendations in the evolving field of antiplatelet therapy.
Summary:
- Atherothrombosis leads to serious ischemic events.
- Antiplatelet therapy, particularly aspirin, is effective in preventing recurrent vascular events.
- Optimal dosing of aspirin and the roles of other agents like clopidogrel require ongoing evaluation.
Impact:
- Provides clinicians with updated information for managing patients at risk of atherothrombotic events.
- Aims to optimize the use of antiplatelet agents for improved patient outcomes.
- Contributes to evidence-based recommendations in antiplatelet therapy for vascular event prevention.